BPC-157 Prices

How it works

What has been studied in humans

Human evidence for BPC-157 is thin and entirely early stage. As of October 2026, no peer-reviewed randomized efficacy trial has been published, and the published reports are three uncontrolled studies with 30 participants in total ^[10][25]. A phase 2 trial is the stage that tests whether a treatment works in participants who have the condition, usually after early safety testing. A PubMed search on October 22, 2026 indexed no record classified as a clinical trial for the compound, and ClinicalTrials.gov listed four registered studies, none with posted results ^[19][20][21]. The BPC-157 human evidence reality check walks through what that record does and does not show.

The knee series was a one-year chart review at a private clinic in Orlando, Florida, covering patients treated in 2019 and 2020 ^[6]. Of 17 patients, 16 were reached by telephone; 11 of the 12 who received BPC-157 alone reported significant improvement, and 3 of the 4 who received BPC-157 plus TB4 did, for 14 of 16 overall. The authors used no validated function or quality-of-life instrument, follow-up varied from 6 months to a year, and the abstract reports no regimen and no adverse-event data ^[6].

The interstitial cystitis study enrolled 12 women aged 39 to 76, mean age 58.3, none of whom had responded to pentosan polysulfate, an approved oral drug for the condition ^[7]. Each woman had one cystoscopy, a camera examination of the bladder, and the regimen reported in the cited trial was a total of 10 mg injected around the inflamed area. All 12 scored 5 of 5 on the Global Response Assessment; 10 reported complete resolution and 2 reported about 80 percent improvement, and no adverse events were recorded ^[7]. Without a control or sham procedure, the result cannot be separated from the response that a procedure itself can produce ^[10].

The intravenous pilot enrolled two adults, a 58-year-old man and a 68-year-old woman, both of whom had received intravenous BPC-157 before ^[8]. The regimen reported in the cited trial was 10 mg in 250 mL of normal saline over one hour on day 1 and 20 mg the same way on day 2, with blood work and vital signs collected before and after. The authors report no measurable effect on markers of heart, liver, kidney or thyroid function or on blood glucose, and no side effects ^[8]. Two participants without a comparator cannot establish general safety, and the study reported no pharmacokinetic results ^[11].

The inflammatory bowel disease program supplies the largest controlled exposure, and it survives only as conference abstracts summarized by FDA ^[25]. The phase 1 enema study gave BPC-157 to 32 healthy participants and recorded the peptide as mostly undetectable in plasma. The 2005 phase 2 abstract randomized 53 patients with mild to moderate ulcerative colitis to an enema formulation or placebo once daily for two weeks and reported Disease Activity Index changes of -3.2 and -1.6 points. FDA judged the abstract inadequate to support efficacy or safety because endpoint definitions, eligibility, statistics and follow-up were not described ^[25].

The reviews reach the same conclusion from different angles. The 2025 orthopaedic review found 36 eligible studies, 35 preclinical and one clinical, and no clinical safety data ^[9]. The 2026 PRISMA review, a systematic review reported to a published standard, included three studies and 30 participants, judged all three poor quality and rated overall certainty very low with GRADE, a formal system for grading evidence ^[10]. A 2026 biopharmaceutical review adds that the clinical data come from three uncontrolled pilots, none of which used a standardized pharmaceutical preparation ^[11].

Registered studies will change this picture if they report. The hamstring trial has two co-primary endpoints, time to return to unrestricted sport and change in MRI-measured injury volume at day 14, and it randomizes participants 1 to 1 to BPC-157 or placebo alongside standardized rehabilitation ^[20]. The rotator cuff pilot lists 30 participants in the registry and measures tendon healing on MRI, patient-reported outcomes, range of motion and grip strength ^[21]. The gummy study measured hs-CRP and IL-6, two inflammatory markers, over eight weeks in 40 adults and completed without posting results ^[22].

Doses studied in human trials

As of October 2026, BPC-157 remains unapproved for any human use and without a completed randomized efficacy trial. Regimens below are those reported in the cited human trials.

Lab and animal studies

The preclinical literature is large, repetitive and concentrated in a small number of groups. A PubMed search on October 22, 2026 returned 228 records, 174 of them with Sikiric P among the authors ^[23]. The 2025 systematic review found 36 eligible studies, 35 of them preclinical, and the 2019 review described the field as dominated by small rodent work from a handful of laboratories ^[9][23]. The models cover muscle, tendon, ligament, bone, skin, gut and blood-vessel injury, and the reported outcomes include faster functional recovery and stronger repaired tissue ^[9].

The gastrointestinal work is the historical core. In the 1992 restraint-stress model, 10 micrograms per kilogram given intraperitoneally protected the stomach lining, and the effect depended on the ovaries, adrenal medulla, thyroid and parathyroid ^[1]. The 1993 report extended the claim across organ systems and species, at microgram and nanogram per kilogram doses, by intraperitoneal, intragastric and local application, with activity after a single dose ^[2]. The 1999 review added pancreas, liver, heart rhythm, blood pressure, wound and fracture healing, and proposed a defence network linking dopamine, nitric oxide, prostaglandin and sensory neuron systems ^[3]. Cytoprotection, the protection of cells from injury before damage occurs, is the concept that ties this work together ^[1][2].

Independent replication in live animals is limited, which makes the 2026 Achilles tendon study notable ^[14]. Thirty-two male Sprague-Dawley rats, 12 weeks old and about 330 grams, had their Achilles tendon cut and repaired and were randomized to four groups of eight. The groups received intraperitoneal saline, BPC-157 at 10 micrograms per kilogram per day, TB-500 at 60 micrograms per kilogram per day, or the combination, for four weeks. Maximum load to failure was higher in both peptide groups but reached significance only with TB-500. Histology scores using the Bonar and Movin systems, two standard grading schemes for tendon structure, improved significantly with TB-500 and with the combination but not with BPC-157 alone, and the combination gave no extra benefit ^[14].

Preclinical safety testing covered mice, rats, rabbits and dogs. Single-dose studies showed no test-related effects, repeat-dose studies were well tolerated apart from a reversible creatinine decrease at 2 mg/kg in dogs, local irritation was mild, and there was no genetic or embryo-fetal toxicity ^[13]. FDA's own review of the same reports noted shortened activated partial thromboplastin time, a clotting test, in rats and prolongation in dogs, higher ALT, a liver enzyme, plus higher glucose and triglycerides, no carcinogenicity studies, and toxicology limited in scope and duration and conducted by routes other than those nominated ^[25]. Pharmacokinetics in rats and dogs showed a plasma half-life under 30 minutes, linear kinetics, intramuscular bioavailability of 14 to 19 percent in rats and 45 to 51 percent in dogs, and excretion through urine and bile ^[12]. The intact peptide is broken into small fragments that rejoin normal amino acid metabolism ^[12].

Research in detail

History and where it stands today

BPC-157 moved from laboratory pharmacology to human pilots, a Croatian development program and a 2026 FDA compounding review.

1. 1999A review of BPC-157 set out activity across stomach, pancreas, liver, heart and vascular injury models ^[3].
2. 2005Pliva developed the peptide in Croatia under the code PL 14736, with inflammatory bowel disease as the lead indication ^[25]. A randomized phase 2 abstract tested an enema formulation in 53 patients with mild to moderate ulcerative colitis and reported a mean Disease Activity Index change of -3.2 points against -1.6 with placebo, with no difference in adverse events; FDA later judged the abstract inadequate to support efficacy or safety ^[25].
3. October 2015A phase 1 study of an oral tablet formulation, PCO-02 or Bepecin, opened with 42 healthy volunteers in a randomized, quadruple-masked design under NCT02637284 ^[19]. The registry lists an unknown status and no posted results ^[19].
4. 2021A one-year chart review at a private clinic in Orlando, Florida, followed 16 patients after knee-joint injection, and 14 reported significant relief ^[6].
5. 2024A pilot in 12 women with interstitial cystitis reported a top score on a global response scale in all 12 after a single treatment around the bladder wall ^[7].
6. 2025An intravenous safety pilot in two adults reported no measurable changes in cardiac, liver, kidney, thyroid or glucose markers ^[8]. The same year, a systematic review of the orthopaedic literature screened 544 articles and included 36 studies, 35 of them preclinical ^[9].
7. February 2026HHS Secretary Robert F. Kennedy Jr. announced that about 14 of the 19 peptides on FDA's Category 2 restricted compounding list would move back to Category 1, which allows compounding with a prescription ^[27]. BPC-157 was on that list, and the change was expected by April 23, 2026, ahead of the July advisory review ^[27].
8. July 2026The July 2026 PCAC vote on BPC-157 came out 8 to 6 with one abstention, on each of the free base and acetate forms, in favor of adding the peptide to the 503A bulk drug substances list ^[17][26]. FDA staff had recommended against listing both forms ^[25].
9. October 2026As of October 2026, BPC-157 is not on the 503A bulks list, and FDA's safety-risks page, current as of April 22, 2026, lists it among previously Category 2 substances whose nominators withdrew them ^[16]. WADA's 2026 Prohibited List names it in class S0 and the NCAA banned list includes it among banned peptide hormones, while FDA still faces a decision on the recommendation and rulemaking the American Journal of Managed Care describes as taking 12 to 24 months ^[24][18][27].

How it compares with related peptides

Side effects and safety signals

Human safety data are sparse, and most of what exists comes from small uncontrolled studies and animal toxicology.

• No side effects were reported after intravenous infusions in two adults at the regimen reported in the cited trial, 10 mg on day 1 and 20 mg on day 2 ^[8].
• No adverse events were reported after a single intravesical treatment, meaning an injection into the bladder wall, in 12 women ^[7].
• The knee chart review reports no adverse-event data at all ^[6].
• FDA's summary of the ulcerative colitis abstracts records headache and flatulence at frequencies similar to placebo, no serious adverse events, and limited safety-monitoring detail ^[25].
• Across mice, rats, rabbits and dogs, single-dose studies showed no test-related effects, repeat-dose studies were well tolerated apart from a reversible creatinine change at 2 mg/kg in dogs, local irritation was mild, and genotoxicity and embryo-fetal toxicity tests were negative ^[13].
• FDA's review of the same studies emphasized clotting-time changes in both directions, higher ALT, glucose and triglycerides, and the absence of carcinogenicity testing, and it judged the toxicology limited in scope and duration and conducted by routes other than those proposed for compounding ^[25].
• FDA's briefing document records three FAERS reports involving injectable BPC-157, none attributable to BPC-157 alone; there are no human reproductive, lactation, pediatric, post-marketing or cancer-incidence data, which matters for a peptide that promotes angiogenesis ^[25].
• Limited reporting in 30 participants cannot establish long-term safety, and the 2026 systematic review rated the certainty of the safety evidence very low ^[10].
• Chemical characterization is the other open area: FDA's review found inconsistent naming across the nomination packages and gaps in impurity, aggregation and endotoxin data for both forms, and those points were central to the staff recommendation against listing ^[25]. Purity and identity testing on vendor certificates is tracked in the COA library.

The future: what's next for BPC-157

The most informative study now running is NCT07437547, a randomized, double-blind, placebo-controlled phase 2 trial in 120 participants with an acute grade II hamstring strain ^[20]. Participants receive BPC-157 or placebo for 14 days alongside standardized rehabilitation, and the co-primary endpoints are time to return to unrestricted sport and change in MRI-assessed injury volume at day 14. The trial began recruiting in February 2026 and has a planned completion date of February 17, 2028 ^[20].

Two more registered studies will add data sooner. NCT07803250 is a 30-participant, quadruple-masked pilot in arthroscopic rotator cuff repair, with daily subcutaneous injections for 90 days and MRI-based tendon healing as an endpoint, scheduled to start in January 2027 ^[21]. NCT07752381 finished in November 2025 after eight weeks of a BPC-157 gummy in 40 adults and has not posted results ^[22]. The older oral tablet study, NCT02637284, still shows an unknown status ^[19].

Regulatory timing is the other live item. FDA must decide whether to accept the advisory committee's recommendation, then complete notice-and-comment rulemaking, a process the American Journal of Managed Care describes as taking 12 to 24 months ^[26][27]. As of October 2026, BPC-157 is not on the 503A bulks list, and FDA's page lists it among previously Category 2 substances withdrawn by their nominators ^[16].

• It is still unknown whether BPC-157 produces any benefit beyond placebo in a randomized trial, and in which indication ^[10][20].
• What human pharmacokinetics and target engagement look like by route remains unclear, given a plasma half-life under 30 minutes in animals and no identified receptor ^[11][12][25].
• Whether long-term exposure to a pro-angiogenic peptide alters cancer or cardiovascular risk is unresolved, because FDA found no carcinogenicity studies and no human cancer-incidence data exist ^[25].
• Whether products can be characterized consistently enough for trials and compounding, including identity, purity, aggregation and endotoxin, is an open technical question ^[16][25].
• Whether the vasorelaxation seen in human artery rings translates into a measurable circulatory effect in humans is not yet known ^[15].